Teva Pharmaceuticals Reports Improved Margins and Growth in Branded Therapies
Teva Pharmaceuticals (TEVA) is successfully executing a strategic pivot from generic medications toward high-margin branded therapies and complex biologics. While third-quarter revenue saw a slight 2% year-over-year decline to $4.4 billion, the company's three primary innovative growth drivers—Austedo, Ajovy, and Uzedy—saw combined sales surge by 33% to $1.1 billion. This shift has significantly bolstered profitability, with non-GAAP gross profit margins reaching a decade high of 58.7%. The company is further strengthening its pipeline with the recent FDA approval of Weltruza for schizophrenia and upcoming potential launches like DARI for asthma. Additionally, Teva's transition to direct trading on the NYSE aims to increase liquidity and accessibility for U.S. institutional investors.
Tickers: $TEVA
Topics: Debt Reduction Pharmaceuticals Profit Margins Revenue